Collexis Names Lenerl Sharp as European Director of Sales

Collexis Holdings, Inc. (OTCBB:CLXS), a leading developer of high
definition search and knowledge discovery software, today announced
the appointment of Lenerl Sharp as the company´s European Director of
Sales. In this position, Sharp will focus on sales of Collexis´ suite
of products to the life science markets. Sharp joins the team after
more than nine years of sales leadership with the multinational
company Elsevier, BV, in Amsterdam, Netherlands, where he served as
the Manager of Global Distribution and Channel Sales for the leading
publisher of science and health information.

"I consider Collexis quite fortunate to have found the talent we
found in Lenerl Sharp," said Collexis CEO Bill Kirkland. "We are
pleased to bring him on board as our European Director of Sales and
believe that his exceptional abilities and international business
perspective will afford a new outlook as well as expand and further
our vision of providing our clients with maximum efficiency with
knowledge retrieval and discovery."

While at Elsevier, Sharp made a significant professional impact
with his contributions and expertise in new product marketing,
business consulting, large contract negotiations and building
strategic business relationships. He holds an MBA in International
Business from University of LaVerne in California and a B.S. in
marketing from Illinois State University.

"I am excited about joining the Collexis team and be a part of a
company that is positioned to be an integral player in the research
community," said Sharp. "Collexis represents the opportunity to bring
institutions text mining and knowledge discovery solutions that go
beyond traditional publishers thanks to its unique technology that
generates expert profiles of researchers to help build research teams,
avoid duplicated work, and combines key research projects to help
stimulate innovation."

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of high definition
search and knowledge discovery software since 1999, is headquartered
in Columbia, South Carolina (USA) with operations in Cincinnati, Ohio,
Geldermalsen, the Netherlands and Cologne, Germany. Collexis now
offers the world´s first pre-populated professional social network for
life science researchers, www.biomedexperts.com. Collexis´ proprietary
technology builds conceptual profiles of text, called Fingerprints,
from documents, Websites, emails and other digitized content and
matches them with a comprehensive list of pre-defined "fingerprinted"
concepts to make research results more relevant and efficient. This
matching of concepts eliminates the ambiguity and lack of priority
associated with word searches. The results are often described as
"finding needles in many haystacks." Through this novel approach,
Collexis can build unique applications to search, index and aggregate
information as well as prioritize, trend and predict data based on
sources in multiple industries without the limitations of language or
dialect. Collexis´ current clients in the public, private and academic
sectors include the Mayo Clinic; Johns Hopkins University; the
University of California, San Francisco; the University of South
Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed
Martin; the World Health Organization; Wellcome Trust; the National
Institutes of Health; and the U.S. Department of Defense. Shares of
Collexis common stock are traded under the symbol CLXS on the OTC
Bulletin Board (OTC BB). For more information, visit www.collexis.com.

Forward-Looking Statements

Some of the statements made in this press release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management´s current expectations and include
known and unknown risks, uncertainties and other factors, many of
which the company is unable to predict or control, that may cause the
company´s actual results or performance to differ materially from any
future results or performance expressed or implied by such
forward-looking statements. These risks and uncertainties are in
addition to other factors detailed from time to time in the company´s
filings with the SEC, including the section entitled "Risk Factors" in
its transition report on Form 10-KSB for the period ended June 30,
2007, as amended. The company cautions investors that any
forward-looking statements made by the company are not necessarily
indicative of future performance. The company is not responsible for
updating the information contained in this press release beyond the
published date, or for changes made to this document by wire services
or Internet services.